PanGenomic Health Subsidiary, MUJN Diagnostics, Announces the Engagement of Hemex Health to Assist in the Development of Brain Health Diagnostics System
VANCOUVER, BC, March 30, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA), is pleased to announce its subsidiary, MUJN Diagnostics Inc. ("MUJN Diagnostics"), has signed a master services agreement with Hemex Health Inc. ("Hemex Health"), a Portland, Oregon-based medical diagnostic device company focused on developing life changing testing solutions for the point-of-care market. Hemex Health will assist MUJN Diagnostics in developing a diagnostics system, which can be used to support patients being treated with alternative therapies for brain health. This system will objectively track the efficacy of a patient's treatment program. As part of this engagement, MUJN Diagnostics will develop proprietary brain biomarker diagnostic panels, and Hemex Health will enhance their Gazelle point of care platform ("Gazelle") to analyze these tests. In March 2023, MUJN Diagnostics and Hemex Health initiated the diagnostic cartridge design phase of the engagement.
"The relationship between MUJN Diagnostics and Hemex Health is expected to help usher in a new platform for integrated healthcare professionals using new brain health therapies to more effectively monitor and treat their patients," said Vincent Lum, CEO and President of MUJN Diagnostics and Co-Founder of PanGenomic Health. "New promising alternative therapies for a variety of brain and mental health conditions and disorders, such as the use of psychedelics as a part of a structured treatment program, need objective data for clinicians and their patients to track and quantify the efficacy of their treatment."
Patti White, CEO of Hemex Health, said: "We designed our Gazelle technology to provide advanced capabilities at point of care, and we're excited to have Gazelle provide the analysis of these new biomarkers."
Peter Galen, Chief Innovation Officer of Hemex Health, added, "Our combined expertise in leading edge diagnostics sensor technology and disease specific biomarker treatment monitoring is expected to provide health care professionals in the field of integrative medicine with tools to improve patient outcomes."
Hemex Health breaks traditional barriers with its innovative diagnostic system that expands the potential of diagnostics for emerging diseases, making accurate tests accessible to new locations and new populations. Gazelle technology was developed in collaboration with Case Western Reserve University. Hemex Health is based in Portland, Oregon, USA. HemexDx, a subsidiary of Hemex Health, is based in Mumbai, India. More information can be found by going to www.hemexhealth.com.
MUJN Diagnostics Inc. is a wholly-owned subsidiary of PanGenomic Health Inc. and is focused on developing a decision support system for alternative healthcare providers. MUJN Diagnostics' decision support system will include biomarker diagnostics, symptom and treatment tracking, and personalized health analytics, with the goal of empowering healthcare providers and their patients toward better outcomes.
PanGenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. The Company's initial focus is to support mental health. Registered as a British Columbia benefit company, PanGenomic Health's mission is to promote and improve the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to the health profile of each individual.
This news release includes certain statements that may be deemed "forward-looking statements", including statements respecting the services to be provided by PanGenomic and the consideration to be paid to PanGenomic. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "would", "project", "should", "believe" and similar expressions are intended to identify forward looking statements. Although PanGenomic believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because PanGenomic can give no assurance that they will prove to be correct. In particular, there is no assurance that MUJN Diagnostics and/or Hemex Health will be able to develop the diagnostic decision support system or other planned diagnostic products within the timeframes expected, or at all. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in PanGenomic's disclosure documents which can be found under PanGenomic's profile on www.sedar.com.
The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.
SOURCE PanGenomic Health Inc.
Jerry Lai, Investor Relations, PanGenomic Health Inc., 778 743 4642, [email protected]; Maryam Marissen, President & CEO, PanGenomic Health Inc., 778 743 4642, [email protected]
Share this article